Overview
AI-driven precision drug design platform automating target selection, molecule generation, and synthesis planning — integrated into Recursion post-acquisition.
Product and company
Exscientia — Biotechnology is a verified product offering linked to the Brel Digital company profile for Exscientia.
Use cases
AI-driven precision drug design platform automating target selection, molecule generation, and synthesis planning — integrated into Recursion post-acquisition.
Target customer
Now internal to Recursion Pharmaceuticals; historically pharmaceutical partners seeking AI-designed clinical candidates.
Technologies
Primary technologies assigned from the linked company profile: Deep Learning, Healthcare Analytics, Machine Learning, Predictive Analytics.
Sources and references
- Official product / company source: https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space
- Supporting source: https://www.exscientia.com/about-us
Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.
Last reviewed
This product profile was last reviewed on 2026-07-14.
Correction request
If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.
Features and capabilities
- AI-driven precision drug design platform automating target selection, molecule generation, and synthesis planning — integrated into Recursion post-acquisition.
Extracted from the linked company product description already verified on Brel. No capabilities were invented.